Effectiveness of combined therapy with angiotensin-converting enzyme inhibitors and statins in reducing mortality in diabetic patients with critical limb ischemia: An observational study

Diabetes Research and Clinical Practice

Volumn 103, Issue 2, 2014, Pages 292-297

  Faglia, Ezio ^a   Clerici, Giacomo ^a   Scatena, Alessia ^a   Caminiti, Maurizio ^a   Curci, Vincenzo ^a   Morabito, Alberto ^b   Prisco, Vincenzo ^c   Greco, Rosaria ^c   Edmonds, Mike ^d  

^a IRCCS MULTIMEDICA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c Fondazione Onlus DeaMedica   (Italy)

^d KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Ace inhibitors Mortality; Critical limb ischemia; Diabetes; Medical therapy; Statins

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLYCOSYLATED HEMOGLOBIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN;

ADULT; AGE; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLOOD PRESSURE MONITORING; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CRITICAL LIMB ISCHEMIA; DIABETIC PATIENT; DIALYSIS; FEMALE; FOLLOW UP; HUMAN; KIDNEY FAILURE; LEG REVASCULARIZATION; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MORTALITY; OBSERVATIONAL STUDY; PRESCRIPTION; PROSPECTIVE STUDY; RISK REDUCTION; SURVIVAL RATE; DIABETES MELLITUS; DIABETIC FOOT; DRUG COMBINATION; KAPLAN MEIER METHOD; MIDDLE AGED; PROGNOSIS; RENAL REPLACEMENT THERAPY; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DIABETES MELLITUS; DIABETIC FOOT; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 84895817510     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2013.12.060     Document Type: Article

References (29)

1. Dosluoglu H.H., Lall P., Harris L.M., Dryjski M.L. Long-term limb salvage and survival after endovascular and open revascularization for critical limb ischemia after adoption of endovascular-first approach by vascular surgeons. J Vasc Surg 2012, 56(2):361-371.
2. Leibson C.L., Ransom J.E., Olson W., Zimmerman B.R., O'fallon W.M., Palumbo P.J. Peripheral arterial disease, diabetes, and mortality. Diabetes Care 2004, 27(12):2843-2849.
3. Uccioli L., Gandini R., Giurato L., Fabiano S., Pampana E., Spallone V., et al. Long-term outcomes of diabetic patients with critical limb ischemia followed in a tertiary referral diabetic foot clinic. Diabetes Care 2010, 33(5):977-982.
4. Abou-Zamzam A.M, Gomez N.R., Molkara A., Banta J.E., Teruya T.H., Killeen J.D., et al. A prospective analysis of critical limb ischemia: factors leading to major primary amputation versus revascularization. Ann Vasc Surg 2007, 21(4):458-463.
5. Young M.J., McCardle J.E., Randall L.E., Barclay J.I. Improved survival of diabetic foot ulcer patients 1995-2008: possible impact of aggressive cardiovascular risk management. Diabetes Care 2008, 31(11):2143-2147.
6. Hiatt W.R. Medical treatment of peripheral arterial disease and claudication. N Engl J Med 2001, 344(21):1608-1621.
7. Feringa H.H., Karagiannis S.E., Vidakovic R. Glycemic control, lipid-lowering treatment, and prognosis in diabetic patients with peripheral atherosclerotic disease. Ann Vasc Surg 2007, 21(6):780-789.
8. Flu H.C., Lardenoye J.H., Veen E.J., Aquarius A.E., Van Berge Henegouwen D.P., Hamming J.F. Morbidity and mortality caused by cardiac adverse events after revascularization for critical limb ischemia. Ann Vasc Surg 2009, 23(5):583-597.
9. Faglia E., Clerici G., Caminiti M., Quarantiello A., Curci V., Morabito A. Advantages of myocardial revascularization after admission for critical limb ischemia in diabetic patients with coronary artery disease: data of a cohort of 564 consecutive patients. J Cardiovasc Med 2008, 9(10):1030-1036.
10. Norgren L., Hiatt W.R., Dormandy J.A., Nehler M.R., Harris K.A., Fowkes F.G., on behalf of the TASC II Working Group Inter-society consensus for the management of peripheral arterial disease (TASC II). Eur J Vasc Endovasc Surg 2007, 33(Suppl):19.
11. Management of peripheral arterial disease (PAD) TransAtlantic Inter-Society Consensus (TASC). Eur J Vasc Endovasc Surg 2000, 19(Suppl A). Si-xxviii, S1-250.
12. Apelqvist J., Larsson J., Agardh C.D. Long-term prognosis for diabetic patients with foot ulcers. J Intern Med 1993, 233(6):485-491.
13. Winkley K., Stahl D., Chalder T., Edmonds M.E., Ismail K. Risk factors associated with adverse outcomes in a population-based prospective cohort study of people with their first diabetic foot ulcer. J Diabetes Complications 2007, 21(6):341-349.
14. Pinto A., Tuttolomondo A., Di Raimondo D., Fernandez P., La Placa S., Di Gati M., et al. Cardiovascular risk profile and morbidity in subjects affected by type 2 diabetes mellitus with and without diabetic foot. Metabolism 2008, 57(5):676-682.
15. Dick F., Ricco J.B., Davies A.H., Cao P., Setacci C., de Donato G., et al. Follow-up after revascularisation. Eur J Vasc Endovasc Surg 2011, 42(Suppl 2):S75-S90.
16. Diehm N., Schmidli J., Setacci C., Ricco J.B., de Donato G., Becker F., et al. Chapter III: Management of cardiovascular risk factors and medical therapy. Eur J Vasc Endovasc Surg 2011, 42(Suppl 2):S33-S42.
17. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Eur Heart J 2011, 32(22):2851-2906.
18. Olin J.W., Allie D.E., Belkin M., Bonow R.O., Casey D.E., Creager M.A., et al. Performance measures for adults with peripheral artery disease: a report of the American College of Cardiology. J Am Coll Cardiol 2010, 56(25):2147-2181.
19. Feringa H.H., van Waning V.H., Bax J.J., Elhendy A., Boersma E., Schouten O., et al. Cardioprotective medication is associated with improved survival in patients with peripheral arterial disease. J Am Coll Cardiol 2006, 47(6):1182-1187.
20. Aiello F.A., Khan A.A., Meltzer A.J., Gallagher K.A., McKinsey J.F., Schneider D.B. Statin therapy is associated with superior clinical outcomes after endovascular treatment of critical limb ischemia. J Vasc Surg 2012, 55(2):371-379.
21. Heart Outcomes Prevention Evaluation Study Investigators Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000, 342(3):145-153.
22. Chi Y.W., Jaff M.R. Optimal risk factor modification and medical management of the patient with peripheral arterial disease. Catheter Cardiovasc Interv 2008, 71(4):475-489.
23. Nanjundappa A., Dieter R.S. Pharmacological interventions on critical limb ischemia in diabetic patients. J Cardiovasc Surg 2012, 53(1):39-43.
24. Brown L.C., Johnson J.A., Majumdar S.R., Tsuyuki R.T., McAlister F.A. Evidence of suboptimal management of cardiovascular risk in patients with type 2 diabetes mellitus and symptomatic atherosclerosis. CMAJ 2004, 171(10):1189-1192.
25. Parekh N., Nanjundappa A., Dieter R.S. Pharmacological interventions on critical limb ischemia in diabetic patients. J Cardiovasc Surg 2012, 53(1):39-43.
26. Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342(3):145-153.
27. Hirsch A.T., Duprez D. The potential role of angiotensin-converting enzyme inhibition in peripheral arterial disease. Vasc Med 2003, 8(4):273-278.
28. American Diabetes Association Standards of Medical Care in diabetes-2012. Diabetes Care 2012, 35(Suppl 1).
29. Tkác I. Effect of intensive glycemic control on cardiovascular outcomes and all-cause mortality in type 2 diabetes: overview and metanalysis of five trials. Diabetes Res Clin Pract 2009, 86(Suppl 1):S57-S62.